Re: Zenith Epigenetics is proud to announce the appointment Dr. Brad Thompson, PhD to our Board of Directors!
posted on
Feb 07, 2022 12:27PM
Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials
I don't know anything about Dr Thompson but the aspect that I like is..."He has taken companies public on the TSX, NASDAQ and former Alberta Stock Exchange, as well as led successful cross-listings (from the TSX to the NASDAQ)."
Any business skill that he can bring to the board and company is welcome from my perspective. I've become quite dissillusioned by the lack of business skills at both companies and it's about time that these companies get down to business.
Perhaps this appointment is a hint that shareholder liquidity is in the works?
GLTA
Toinv